
Tennis star Monica Seles reveals she has neuromuscular autoimmune disease
'I would be playing with some kids or family members, and I would miss a ball. I was like, 'Yeah, I see two balls.' These are obviously symptoms that you can't ignore,' Seles said. 'And, for me, this is when this journey started. And it took me quite some time to really absorb it, speak openly about it, because it's a difficult one. It affects my day-to-day life quite a lot.'
The 51-year-old Seles, who won her first major trophy at age 16 at the 1990 French Open and played her last match in 2003, said she was diagnosed with myasthenia gravis three years ago and is speaking publicly about it for the first time ahead of the U.S. Open, which starts on Aug. 24, to raise awareness about what is known as MG.
The National Institute of Neurological Disorders and Stroke calls it 'a chronic neuromuscular disease that causes weakness in the voluntary muscles' and 'most commonly impacts young adult women (under 40) and older men (over 60) but . . . can occur at any age, including childhood.'
Seles said she'd never heard of the condition until seeing a doctor and being referred to a neurologist after noticing symptoms such as double vision and weakness in her arms – 'just blowing my hair out . . . became very difficult,' she said – and legs.
'When I got diagnosed, I was like, 'What?!'' said Seles, who is partnering with argenx, an immunology company headquartered in the Netherlands, to promote their Go for Greater campaign. 'So this is where – I can't emphasize enough – I wish I had somebody like me speak up about it.'
From the archive: Seles had no greater triumph than the 1995 Canadian Open
It's been three decades since Seles returned to competition at the 1995 U.S. Open, making it to the final, more than two years after she was attacked by a man with a knife at a tournament in Hamburg, Germany.
'The way they welcomed me . . . after my stabbing, I will never forget,' Seles said about the fans in New York. 'Those are the moments that stay with you.'
She talks about learning to live a 'new normal' nowadays and characterized her health as another in a series of life steps that required adapting.
'I had to, in tennis terms, I guess, reset – hard reset – a few times. I call my first hard reset when I came to the U.S. as a young 13-year-old (from Yugoslavia). Didn't speak the language; left my family. It's a very tough time. Then, obviously, becoming a great player, it's a reset, too, because the fame, money, the attention, changes (everything), and it's hard as a 16-year-old to deal with all that. Then obviously my stabbing – I had to do a huge reset,' Seles said.
'And then, really, being diagnosed with myasthenia gravis: another reset. But one thing, as I tell kids that I mentor: 'You've got to always adjust. That ball is bouncing, and you've just got to adjust,'' she added. 'And that's what I'm doing now.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Globe and Mail
a day ago
- Globe and Mail
Conservatives call for investigation of Spanish drugmakers' use of Canadian-donated blood plasma
Conservative MPs are calling for a parliamentary investigation into Spanish drugmaker Grifols's GIFOF use of Canadian-donated blood plasma to make medicines for sale abroad. The call follows a Globe and Mail investigation that found Canadian Blood Services is selling some blood components to Grifols to manufacture a product called albumin, as part of a complex arrangement between the international pharmaceutical company and the Canadian charity to collect and process blood plasma. Plasma is a straw-coloured fluid in blood used for transfusions and to make therapies such as immunoglobulin, commonly used for people with immune disorders. Both CBS and Grifols collect plasma at donation centres across Canada, and Grifols pays donors while CBS does not. Hamilton rebukes Canadian Blood Services, Grifols over paying for blood plasma donations In a letter sent Wednesday to House of Commons health committee chair Hedy Fry, six Conservative MPs called the details in the story 'troubling.' The letter also references the fact that the private-equity arm of Brookfield Asset Management Ltd. BAM-T explored a bid to buy Grifols last year. At the time of the bid, Mark Carney was chair of the board of Brookfield, one of the world's largest asset managers, but he stepped down in January to pursue the leadership of the Liberal Party and ultimately became Prime Minister. Brookfield said in April it had dropped its bid for Grifols. 'We urge you to recall the Standing Committee on Health to investigate both the use of Canadian-donated plasma by Grifols and the potential conflicts of interest arising from the Prime Minister's investments in Brookfield Asset Management, given its attempts to acquire Grifols,' wrote the letter's signatories, including Conservative shadow health minister Dan Mazier. 'Canadians expect their donated blood plasma to save lives in Canada and not to be turned into profits for foreign companies or the Prime Minister.' The Canadian Health Coalition, a progressive group that advocates for the public health care system, said it also supported the call for a parliamentary investigation. 'I think every member of Parliament deserves an explanation from Canadian Blood Services about the murky details of its agreement with Grifols,' said Steven Staples, the group's national director of policy and advocacy. CBS has had a lengthy association with Grifols. The Spanish drugmaker has been a long-time supplier of immunoglobulin and consulted with CBS on a national plasma-collection strategy before the agency announced a formal partnership in 2022. Under the 15-year agreement, Grifols acts as CBS's 'agent' in Ontario, allowing the company to get around a legal ban on paying for plasma donations. In a statement, Grifols said it is 'proud of our pioneering, long-term agreement with Canadian Blood Services to help Canada reach self-sufficiency in immunoglobulins. We continue to follow the agreement to the letter and deliver on our commitments.' CBS said the partnership was necessary to boost the domestic supply of immunoglobulin, which has faced global shortages. CBS said it currently meets 27 per cent of its plasma needs domestically, compared with 15 per cent before 2022. The agency said Grifols's medicine being sold abroad is made from 'byproducts' of the immunoglobulin manufacturing process, and the arrangement lowers the manufacturing cost to CBS. Plasma therapies make up an enormous share of CBS's annual budget. It spent $913-million on 'plasma protein and related products' last year, according to its 2024 annual report, about 60 per cent of its expenses that year. Nearly all of its revenue comes from provincial and territorial governments.


Globe and Mail
a day ago
- Globe and Mail
Neuromyelitis Optica Spectrum Disorder Market Poised for Transformation with New Disease-Modifying Therapies and Regulatory Approvals
DelveInsight projects strong NMOSD market growth in the 7MM through 2032, fueled by disease-modifying therapies and key approvals. Leading NMOSD companies include RemeGen, Alexion, Reistone Biopharma, Nihon Pharmaceutical, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, TG Therapeutics, ENDECE, Boston Pharmaceuticals, and NovelMed, advancing novel mechanisms such as complement inhibition and B-cell depletion. DelveInsight's ' Neuromyelitis Optica Spectrum Disorder Market Insight, Epidemiology And Market Forecast - 2032 ' report delivers a comprehensive analysis of the GnRH Receptor Antagonist market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key Takeaways Market size projection: As per DelveInsight's analysis, the total market size of Neuromyelitis Optica Spectrum Disorder in the 7MM is expected to surge significantly by 2032, with comprehensive coverage across the United States, EU4 countries (Germany, Spain, Italy, and France), the United Kingdom, and Japan during the forecast period from 2024-2032. Patient population data: The report provides the total Neuromyelitis Optica Spectrum Disorder potential patient pool with detailed epidemiology segmentation across all seven major markets, including historical patient data from 2019 and forecasted trends through 2032, encompassing diagnosed patient pools and treatment-eligible populations. Key companies: Leading Neuromyelitis Optica Spectrum Disorder companies such as RemeGen, Alexion Pharmaceuticals, Reistone Biopharma, Nihon Pharmaceutical, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, TG Therapeutics, ENDECE, Boston Pharmaceuticals, NovelMed, and others are actively developing innovative therapeutic solutions. Pipeline assets: The comprehensive pipeline analysis covers emerging therapies across Phase II and Phase III development stages, with detailed therapeutic candidate profiles representing diverse mechanisms of action and novel approaches to address current treatment limitations. In April 2025, UPLIZNA® (inebilizumab-cdon) received FDA approval for Immunoglobulin G4-related disease. It represents the continued expansion of this therapy that was originally approved for AQP4-IgG+ NMOSD patients. Discover recent advancements in the Neuromyelitis Optica Spectrum Disorder treatment landscape @ Neuromyelitis Optica Spectrum Disorder Recent Developments. Neuromyelitis Optica Spectrum Disorder Market Dynamics The Neuromyelitis Optica Spectrum Disorder market represents an evolving therapeutic landscape characterized by significant unmet medical needs and emerging treatment paradigms. The current market reflects a critical juncture where traditional treatment approaches are being supplemented by innovative therapeutic strategies targeting specific disease mechanisms. The Neuromyelitis Optica Spectrum Disorder market drivers include increased disease awareness, improved diagnostic capabilities, and growing recognition of NMOSD as a distinct clinical entity requiring specialized treatment approaches. The market's evolution is fundamentally supported by advancing scientific understanding of NMOSD pathophysiology, particularly the role of aquaporin-4 antibodies and complement-mediated inflammatory processes. This enhanced mechanistic insight has enabled the development of targeted therapeutic interventions that address underlying disease mechanisms rather than merely managing symptoms. The therapeutic rationale for emerging treatments centers on complement inhibition, B-cell depletion, and immunomodulatory approaches designed to prevent relapse occurrence and minimize neurological disability progression. The neuromyelitis optica spectrum disorder market clinical development activity demonstrates robust industry engagement, with multiple therapeutic candidates progressing through Phase II and Phase III trials. The pipeline reflects diverse therapeutic approaches, including monoclonal antibodies, small molecules, and biologics targeting different aspects of NMOSD pathogenesis. This diversified development strategy indicates industry confidence in market potential and commitment to addressing varied patient needs across different disease stages and phenotypes. The neuromyelitis optica spectrum disorder competitive landscape reveals significant pharmaceutical industry participation, with established biotechnology companies and emerging biotech firms pursuing complementary development strategies. Strategic collaborations between industry partners and academic institutions are accelerating research progress and enabling risk-sharing arrangements that support continued investment in this rare disease area. Market positioning strategies emphasize differentiation through mechanism of action, safety profiles, and administration convenience. Current Neuromyelitis Optica Spectrum Disorder market barriers include the rarity of NMOSD, which complicates clinical trial design and patient recruitment, while regulatory pathways for rare diseases present both opportunities through expedited review processes and challenges related to evidence generation requirements. Market opportunities are substantial, given the high unmet medical need, potential for premium pricing in rare disease segments, and expanding global awareness leading to improved diagnosis rates. The future neuromyelitis optica spectrum disorder market outlook indicates sustained growth driven by pipeline maturation, regulatory approvals, and expanding treatment accessibility. Market expectations center on the introduction of disease-modifying therapies that can fundamentally alter NMOSD disease trajectory, representing a paradigm shift from current symptomatic management approaches toward comprehensive disease control. Download the Neuromyelitis Optica Spectrum Disorder Market report to understand which factors are driving the therapeutic market @ Neuromyelitis Optica Spectrum Disorder Market Trends. Neuromyelitis Optica Spectrum Disorder Epidemiology The Neuromyelitis Optica Spectrum Disorder epidemiology across the seven major markets reveals significant geographic and demographic variations that influence market dynamics and therapeutic development strategies. The comprehensive epidemiological analysis encompasses the United States, EU5 countries, including Germany, France, Italy, Spain, and the United Kingdom, plus Japan, representing the most significant commercial markets for NMOSD therapeutics. Historical epidemiology data spanning from 2019 provides a baseline understanding of neuromyelitis optica spectrum disorder prevalence patterns, while forecasted trends through 2032 illuminate evolving patient population dynamics driven by improved diagnostic awareness and refined clinical criteria. The neuromyelitis optica spectrum disorder epidemiology segmentation within the report addresses multiple patient population categories, including total diagnosed cases, treatment-eligible patients, and those receiving current therapeutic interventions. This segmentation approach enables precise market sizing and facilitates targeted therapeutic development strategies. The analysis reveals geographic variations in NMOSD prevalence, with certain regions demonstrating higher disease burden potentially related to genetic predisposition, environmental factors, or diagnostic accessibility differences. Total treated cases encompass patients currently receiving therapeutic interventions, ranging from immunosuppressive therapies to symptomatic management approaches. This metric provides insight into current treatment penetration and identifies opportunities for therapeutic improvement and market expansion. Geographic segmentation across the 7MM breakdown reveals market-specific opportunities and challenges, with developed markets typically demonstrating higher diagnostic rates and treatment accessibility compared to emerging regions. The forecast period through 2032 anticipates continued growth in diagnosed patient populations, driven by enhanced physician awareness, improved diagnostic technologies, and expanding healthcare infrastructure accessibility. Discover evolving trends in the Neuromyelitis Optica Spectrum Disorder patient pool forecasts @ Neuromyelitis Optica Spectrum Disorder Epidemiology Analysis. Key Neuromyelitis Optica Spectrum Disorder Companies and Treatment Market The clinical and regulatory landscape for Neuromyelitis Optica Spectrum Disorder reflects a dynamic environment where traditional treatment approaches are being transformed by innovative therapeutic strategies. Current treatment options primarily consist of immunosuppressive therapies and corticosteroids for acute management, along with off-label use of various immunomodulatory agents for relapse prevention. However, these conventional approaches often provide inadequate disease control and carry significant long-term safety concerns, creating substantial opportunities for targeted therapeutic interventions. Key neuromyelitis optica spectrum disorder companies include RemeGen with their complement inhibition platform, Alexion Pharmaceuticals leveraging their expertise in complement-mediated disorders, Reistone Biopharma developing innovative immunomodulatory approaches, and Nihon Pharmaceutical pursuing region-specific therapeutic strategies. Additional significant contributors include Harbour BioMed with their biologics platform, Bio-Thera Solutions focusing on biosimilar and novel therapeutic development, and Abide Therapeutics targeting specific enzymatic pathways. The landscape also features Bionure's neuroprotective approaches, TG Therapeutics' immunomodulatory strategies, ENDECE's innovative therapeutic platforms, Boston Pharmaceuticals' targeted interventions, and NovelMed's comprehensive development programs. Neuromyelitis Optica Spectrum Disorder market positioning strategies reflect the critical importance of demonstrating superior efficacy compared to current standard-of-care approaches while maintaining acceptable safety profiles. Companies are emphasizing mechanism-of-action differentiation, with some focusing on preventing relapse occurrence, others targeting neurological recovery, and several pursuing comprehensive approaches addressing both inflammatory control and neuroprotection. Neuromyelitis Optica Spectrum Disorder drug profiles within the pipeline demonstrate diverse therapeutic rationales, ranging from complement cascade inhibition to selective immune cell targeting. Development status varies across the portfolio, with some candidates approaching regulatory submission while others are in early clinical evaluation phases. Clinical applications span acute treatment settings, maintenance therapy for relapse prevention, and combination approaches designed to optimize long-term outcomes. Recent Neuromyelitis Optica Spectrum Disorder development milestones include advancing clinical trials, regulatory designations such as orphan drug status and fast-track designations, and strategic partnerships enabling accelerated development timelines. Commercial arrangements reflect the collaborative nature of rare disease development, with licensing deals and strategic collaborations enabling resource sharing and risk distribution across multiple development programs. Discover which companies are innovating in the Neuromyelitis Optica Spectrum Disorder treatment landscape @ Neuromyelitis Optica Spectrum Disorder Competitive Landscape. Conclusion The Neuromyelitis Optica Spectrum Disorder market represents a compelling therapeutic opportunity characterized by significant unmet medical needs, robust pipeline development, and expanding patient identification. DelveInsight's comprehensive analysis reveals a market poised for substantial transformation through 2032, driven by innovative therapeutic approaches, enhanced disease understanding, and growing clinical awareness. The convergence of scientific advancement, industry investment, and regulatory support creates an environment conducive to therapeutic breakthroughs that could fundamentally alter NMOSD treatment paradigms and significantly improve patient outcomes across the seven major global markets. Table of Contents 1. Key Insights 2. Executive Summary of Neuromyelitis Optica Spectrum Disorder 3. Competitive Intelligence Analysis for Neuromyelitis Optica Spectrum Disorder 4. Neuromyelitis Optica Spectrum Disorder Market Overview at a Glance 5. Neuromyelitis Optica Spectrum Disorder: Disease Background and Overview 6. Neuromyelitis Optica Spectrum Disorder Patient Journey 7. Neuromyelitis Optica Spectrum Disorder Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Neuromyelitis Optica Spectrum Disorder Unmet Needs 10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder Treatment 11. Neuromyelitis Optica Spectrum Disorder Marketed Products 12. Neuromyelitis Optica Spectrum Disorder Emerging Therapies 13. Neuromyelitis Optica Spectrum Disorder: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of Neuromyelitis Optica Spectrum Disorder 17. KOL Views 18. Neuromyelitis Optica Spectrum Disorder Market Drivers 19. Neuromyelitis Optica Spectrum Disorder Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:


CBC
2 days ago
- CBC
Tennis great Monica Seles reveals her myasthenia gravis diagnosis
Monica Seles first noticed the symptoms of myasthenia gravis — a neuromuscular autoimmune disease she discussed during a recent interview with The Associated Press — while she was swinging a racket the way she'd done so many times during, and after, a career that included nine Grand Slam titles and a place in the International Tennis Hall of Fame. "I would be playing with some kids or family members, and I would miss a ball. I was like, `Yeah, I see two balls.' These are obviously symptoms that you can't ignore," Seles said. "And, for me, this is when this journey started. And it took me quite some time to really absorb it, speak openly about it, because it's a difficult one. It affects my day-to-day life quite a lot." The 51-year-old Seles, who won her first major trophy at age 16 at the 1990 French Open and played her last match in 2003, said she was diagnosed with myasthenia gravis three years ago and is speaking publicly about it for the first time ahead of the U.S. Open, which starts on Aug. 24, to raise awareness about what is known as MG. The National Institute of Neurological Disorders and Stroke calls it "a chronic neuromuscular disease that causes weakness in the voluntary muscles" and "most commonly impacts young adult women [under 40] and older men [over 60] but ... can occur at any age, including childhood." How Victoria Mboko stunned the tennis world to win her 1st career title Seles said she'd never heard of the condition until seeing a doctor and being referred to a neurologist after noticing symptoms such as double vision and weakness in her arms — "just blowing my hair out ... became very difficult," she said — and legs. "When I got diagnosed, I was like, `What?!"' said Seles, who is partnering with argenx, an immunology company headquartered in the Netherlands, to promote their Go for Greater campaign. "So this is where — I can't emphasize enough — I wish I had somebody like me speak up about it." It's been three decades since Seles returned to competition at the 1995 U.S. Open, making it to the final, more than two years after she was attacked by a man with a knife at a tournament in Hamburg, Germany. "The way they welcomed me ... after my stabbing, I will never forget," Seles said about the fans in New York. "Those are the moments that stay with you." She talks about learning to live a "new normal" nowadays and characterized her health as another in a series of life steps that required adapting. "I had to, in tennis terms, I guess, reset — hard reset — a few times. I call my first hard reset when I came to the U.S. as a young 13-year-old [from Yugoslavia]. Didn't speak the language; left my family. It's a very tough time. Then, obviously, becoming a great player, it's a reset, too, because the fame, money, the attention, changes [everything], and it's hard as a 16-year-old to deal with all that. Then obviously my stabbing — I had to do a huge reset," Seles said. "And then, really, being diagnosed with myasthenia gravis: another reset. But one thing, as I tell kids that I mentor: `You've got to always adjust. That ball is bouncing, and you've just got to adjust,"' she added. "And that's what I'm doing now." WATCH | Victoria Mboko visits CBC Sports to discuss National Bank Open win: Victoria Mboko on her historic National Bank Open title and what's next 23 hours ago CBC Sports' Anastasia Bucsis chats with Victoria Mboko after her historic National Bank Open victory. The Canadian tennis star reflects on the moment, shares her goals for the future, and reveals what's next in her journey.